Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
A phase 1/2 trial of Opevesostat, Olaparib, Docetaxel, Cabazitaxel, Dexamethasone and Prednisone in prostate cancer, run by Merck Sharp & Dohme LLC, now recruiting.
Overview
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) is a phase 1/2 interventional study registered as NCT06353386 by Merck Sharp & Dohme LLC, with 220 participants planned, started 2024-05-20 and due to reach its primary completion in 2029-01-15. Interventions recorded: Opevesostat, Olaparib, Docetaxel, Cabazitaxel, Fludrocortisone acetate and Dexamethasone.
Similar pages
not linked directly; found by shared links- TrialA Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Shares Opevesostat, Docetaxel, Merck & Co. (MSD), Prostate cancer and the tag pipeline.
- TrialA Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
Shares Opevesostat, Dexamethasone, Merck & Co. (MSD) and the tag pipeline.
- TrialA Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Shares Prednisone, Docetaxel, Prostate cancer and the tag pipeline.
- TrialEfficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
Shares Olaparib, Merck & Co. (MSD) and the tag pipeline.
- TrialOlaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Shares Olaparib, Merck & Co. (MSD) and the tag pipeline.
- TrialA Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
Shares Prednisone, Prostate cancer and the tag pipeline.
- TrialSubstudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
Shares Docetaxel, Merck & Co. (MSD) and the tag pipeline.
- TrialA Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
Shares Prednisone, Prostate cancer and the tag pipeline.